Roth Capital analyst Debjit Chattopadhyay reiterated a Buy and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $45.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital SaysMay 21, 2015 11:25 AM BofA/Merrill Lynch Downgrades Sarepta Therapeutic (SRPT) to NeutralMay 21, 2015 7:38 AM Sarepta Therapeutic (SRPT) Has 100% Upside, 50% Downside - Deutsche BankMay 20, 2015 1:34 PM Cowen Maintains Neutral View on Sarepta (SRPT) Despite Rolling NDA for EteplirsenMay 20, 2015 9:01 AM Sarepta (SRPT) PT Raised to $25 at Wedbush on Go-Ahead for Eteplirsen NDAMay 20, 2015 7:30 AM Piper Jaffray Remains on Sidelines with Sarepta (SRPT) Despite Rolling NDA For EteplirsenMay 20, 2015 7:08 AM UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:54 AM SunTrust Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:53 AM BioMarin's (BMRN) Confidence in Drisapersen Approvability Has Increased, Jefferies SaysMay 20, 2015 6:45 AM Sarepta (SRPT) PT Boosted to $34 at Baird Amid Rolling NDA SubmissionMay 20, 2015 6:19 AM After-Hours Stock Movers 05/19: (SRPT) (DY) (CSC) Higher; (ETSY) (CISG) (NCLH) Lower (more..)May 19, 2015 6:07 PM Sarepta Therapeutics (SRPT) Will Initiate Rolling NDA for EteplirsenMay 19, 2015 4:00 PM Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDAMay 19, 2015 4:00 PM